CTIS2022-502151-54-00招募中1 期
Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain - DISCOVER_(MBP)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 558
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Signed and dated informed consent form, Completed painDETECT questionnaire with 20 or more score points, Patients with chronic back pain since at least 3 months, Female and male patients (= 18 years), Patients with more than 1 year life expectancy, Patients with optimized sCPT on study entry as defined in section 3.1.1 and section 3.1.3 of the study protocol, Willingness of study patients of both sexes to use reliable contraception during study participation and for three months after taking the last study medication, Good command of German language, in order to understand questionnaires in German, Current moderate to severe pain with pain intensity > 5 on Numeric Rating Scale (NRS, 0 - 10) and thus an existing need for further pain therapy, Completed QUISS (Quantification Inventory for Somatoform Syndromes) questionnaire with 45 or less score points
排除标准
- •Medical history of hypersensitivity or intolerance to the investigational product or its ingredients or to ingredients of similar chemical structure, Known history of severe cardiovascular disease, Known history of or acute mental illness such as severe depression, psychosis, bipolar disorder, mania, anxiety, or obsessive-compulsive disorder, Known history of addictive disease (e.g., alcohol, medication, drug addiction), Answered during Screening less than 12 times of 18 the pain intensity (NRS) inquiry, Laboratory liver values: Alanine aminotransferase (ALT, GPT) > 3 x ULN (Upper Limit of Normal range), Aspartate aminotransferase (AST, GOT) > 3 x ULN, Alkaline phosphatase (AP) > 2.5 x ULN, Bilirubin > 1.5 x ULN, Laboratory renal value: Serum creatinine > 1.5 ULN, Known intolerance to cannabinoids or cannabis products, Participation in another clinical trial within the last four weeks prior to inclusion, Pregnant or nursing women (as excluded by pregnancy testing at visit 1 for women of childbearing potential), Other medical conditions that do not allow the trial subject to appraise the nature, scope, and potential consequences of the clinical trial, Indications that the trial subject is unlikely to comply with the study protocol (e.g., unwillingness to cooperate), Known use of medicinal cannabis products within the last 8 weeks, Active malignant tumor disease, tumor pain, or other dominant severe pain other than that of the study indication, Known history of severe liver or kidney diseases
研究者
相似试验
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any GenesisChronic pain due to central Neuropathy of any GenesisCTIS2022-500899-66-00Cannaxan GmbH558
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic PolyneuropathyChronic pain due to diabetic polyneuropathyCTIS2022-500897-32-00Cannaxan GmbH558
招募中
1 期
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral NeuropathyChronic Pain due to traumatic or post-operative peripheral NeuropathyCTIS2022-500898-13-00Cannaxan GmbH558
未知
3 期
Safety and efficacy of AIN457 in patients with active non-infectious uveitisJPRN-jRCT2080221051ovartis Pharma K.K.208
未知
Unknown
A confirmatory study of APTA-2217 in patients with chronic obstructive pulmonary disease (A placebo-controlled double-blind, parallel group study)JPRN-jRCT2080220095Mitsubishi Tanabe Pharma was the original trial sponsor; however Astra Zeneca is now the Responsible Party